Global research trends in CAR-T cell therapy for solid tumors: A comprehensive visualization and bibliometric study (2012–2023)

References

• Dana H, Chalbatani GM, Jalali SA, Mirzaei HR, Grupp SA, Suarez ER, Rapôso C, Webster TJ. CAR-T cells: early successes in blood cancer and challenges in solid tumors. Acta Pharm Sin B. 2021;11(5):1129–17. doi:10.1016/j.apsb.2020.10.020. Epub 2021/06/08. PubMed PMID: 34094824; PubMed Central PMCID: PMCPMC8144892.
   PubMed Web of Science ®Google Scholar
• Razavi AS, Loskog A, Razi S, Rezaei N. The signaling and the metabolic differences of various CAR T cell designs. Int Immunopharmacol. 2023;114:109593. doi:10.1016/j.intimp.2022.109593. Epub 2023/01/27. PubMed PMID: 36700773.
   PubMed Web of Science ®Google Scholar
• Wu L, Chen J, Cai R, Wang X, Liu Y, Zheng Q, Li L. Difference in efficacy and safety of anti-CD19 chimeric antigen receptor T-cell therapy containing 4-1BB and CD28 co-stimulatory domains for B-cell acute lymphoblastic leukemia. Cancers. 2023;15(10):2767. doi: 10.3390/cancers15102767. Epub 2023/06/22. PubMed PMID: 37345104; PubMed Central PMCID: PMCPMC10216493.
   PubMed Web of Science ®Google Scholar
• Moreno-Cortes E, Franco-Fuquen P, Garcia-Robledo JE, Forero J, Booth N, Castro JE. ICOS and OX40 tandem co-stimulation enhances CAR T-cell cytotoxicity and promotes T-cell persistence phenotype. Front Oncol. 2023;13:1200914. doi:10.3389/fonc.2023.1200914. Epub 2023/09/18. PubMed PMID: 37719008; PubMed Central PMCID: PMCPMC10502212.
   PubMed Web of Science ®Google Scholar
• Khorasani ABS, Sanaei MJ, Pourbagheri-Sigaroodi A, Ghaffari SH, Bashash D. CAR T cell therapy in solid tumors; with an extensive focus on obstacles and strategies to overcome the challenges. Int Immunopharmacol. 2021;101(Pt B):108260. doi:10.1016/j.intimp.2021.108260. Epub 2021/10/23. PubMed PMID: 34678690.
   PubMedGoogle Scholar
• Andrea AE, Chiron A, Mallah S, Bessoles S, Sarrabayrouse G, Hacein-Bey-Abina S. Advances in CAR-T cell genetic engineering strategies to overcome hurdles in solid tumors treatment. Front Immunol. 2022;13:830292. doi:10.3389/fimmu.2022.830292. Epub 2022/02/26. PubMed PMID: 35211124; PubMed Central PMCID: PMCPMC8861853.
   PubMed Web of Science ®Google Scholar
• Chen Z, Pan H, Luo Y, Yin T, Zhang B, Liao J, Wang M, Tang X, Huang G, Deng G, et al. Nanoengineered CAR-T biohybrids for solid tumor immunotherapy with microenvironment photothermal-remodeling strategy. Small (Weinheim Bergstrasse, Germany). 2021;17(14):e2007494. doi:10.1002/smll.202007494. Epub 2021/03/13. PubMed PMID: 33711191.
   PubMed Web of Science ®Google Scholar
• Liu G, Rui W, Zhao X, Lin X. Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment. Cell Mol Immunol. 2021;18(5):1085–95. doi:10.1038/s41423-021-00655-2. Epub 2021/04/01. PubMed PMID: 33785843; PubMed Central PMCID: PMCPMC8093220.
   PubMed Web of Science ®Google Scholar
• Wang A, Lv T, Song Y. Tandem CAR-T cells targeting MUC1 and PSCA combined with anti-PD-1 antibody exhibit potent preclinical activity against non-small cell lung cancer. Cell Immunol. 2023;391-392:104760. doi:10.1016/j.cellimm.2023.104760. Epub 2023/09/04. PubMed PMID: 37660477.
   PubMed Web of Science ®Google Scholar
• Wang X, Lai Z, Pang Y, Sun Q, Yang W, Wang W. PD-1 blocking strategy for enhancing the anti-tumor effect of CAR T cells targeted CD105. Heliyon. 2023;9(1):e12688. doi:10.1016/j.heliyon.2022.e12688. Epub 2023/01/24. PubMed PMID: 36685461; PubMed Central PMCID: PMCPMC9849980.
   PubMed Web of Science ®Google Scholar
• Wang AX, Ong XJ, D’Souza C, Neeson PJ, Zhu JJ. Combining chemotherapy with CAR-T cell therapy in treating solid tumors. Front Immunol. 2023;14:1140541. doi:10.3389/fimmu.2023.1140541. Epub 2023/03/24. PubMed PMID: 36949946; PubMed Central PMCID: PMCPMC10026332.
   PubMed Web of Science ®Google Scholar
• Fan J, Adams A, Sieg N, Heger JM, Gödel P, Kutsch N, Kaul D, Teichert M, von Tresckow B, Bücklein V, et al. Potential synergy between radiotherapy and CAR T-cells - a multicentric analysis of the role of radiotherapy in the combination of CAR T cell therapy. Radiother Oncol. 2023;183:109580. doi:10.1016/j.radonc.2023.109580. Epub 2023/02/27. PubMed PMID: 36842663.
   PubMed Web of Science ®Google Scholar
• Ventin M, Cattaneo G, Maggs L, Jia J, Arya S, Ferrone S, Wang X, Ferrone CR. B7-H3-targeted CAR T cell activity is enhanced by radiotherapy in solid cancers. Front Oncol. 2023;13:1193963. doi:10.3389/fonc.2023.1193963. Epub 2023/07/24. PubMed PMID: 37483496; PubMed Central PMCID: PMCPMC10361748.
   PubMed Web of Science ®Google Scholar
• Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, Cherif H, Uddin S, Steinhoff M, Marincola FM, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22(1):20. doi:10.1186/s12943-023-01723-z. Epub 2023/02/01. PubMed PMID: 36717905; PubMed Central PMCID: PMCPMC9885707.
   PubMed Web of Science ®Google Scholar
• Chen C, Hu Z, Liu S, Tseng H. Emerging trends in regenerative medicine: a scientometric analysis in CiteSpace. Expert Opin Biol Ther. 2012;12(5):593–608. doi: 10.1517/14712598.2012.674507. Epub 2012/03/27. PubMed PMID: 22443895.
   PubMed Web of Science ®Google Scholar
• Chen C. Searching for intellectual turning points: progressive knowledge domain visualization. Proc Natl Acad Sci USA. 2004;101 (Suppl 1):5303–10. doi:10.1073/pnas.0307513100. Epub 2004/01/16. PubMed PMID: 14724295; PubMed Central PMCID: PMCPMC387312.
   PubMed Web of Science ®Google Scholar
• van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523–38. doi:10.1007/s11192-009-0146-3. Epub 2010/06/30. PubMed PMID: 20585380; PubMed Central PMCID: PMCPMC2883932.
   PubMed Web of Science ®Google Scholar
• O’Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9(399):eaaa0984. doi:10.1126/scitranslmed.aaa0984. Epub 2017/07/21. PubMed PMID: 28724573; PubMed Central PMCID: PMCPMC5762203.
   PubMed Web of Science ®Google Scholar
• Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2016;375(26):2561–9. doi:10.1056/NEJMoa1610497. Epub 2016/12/29. PubMed PMID: 28029927; PubMed Central PMCID: PMCPMC5390684.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D, Robertson C, Gray TL, Diouf O, Wakefield A, et al. HER2-specific chimeric antigen receptor–modified virus-specific T cells for progressive glioblastoma. JAMA Oncol. 2017;3(8):1094–101. doi:10.1001/jamaoncol.2017.0184. Epub 2017/04/21. PubMed PMID: 28426845; PubMed Central PMCID: PMCPMC5747970.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A, et al. Human epidermal growth factor receptor 2 (HER2) –specific chimeric antigen receptor–modified T cells for the immunotherapy of HER2-positive sarcoma. JCO. 2015;33(15):1688–96. doi:10.1200/jco.2014.58.0225. Epub 2015/03/25. PubMed PMID: 25800760; PubMed Central PMCID: PMCPMC4429176.
   PubMed Web of Science ®Google Scholar
• Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, Song M, Miele MM, Li Z, Wang P, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36(9):847–56. doi:10.1038/nbt.4195. Epub 2018/08/14. PubMed PMID: 30102295; PubMed Central PMCID: PMCPMC6126939.
   PubMed Web of Science ®Google Scholar
• Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, Tamada K. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol. 2018;36(4):346–51. doi:10.1038/nbt.4086. Epub 2018/03/06. PubMed PMID: 29505028.
   PubMed Web of Science ®Google Scholar
• Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126(8):3130–44. doi:10.1172/jci83092. Epub 2016/07/28. PubMed PMID: 27454297; PubMed Central PMCID: PMCPMC4966328.
   PubMed Web of Science ®Google Scholar
• Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJ, Hamieh M, Cunanan KM, Odak A, Gönen M, Sadelain M. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2017;543(7643):113–17. doi:10.1038/nature21405. Epub 2017/02/23. PubMed PMID: 28225754; PubMed Central PMCID: PMCPMC5558614.
   PubMed Web of Science ®Google Scholar
• Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, Rietberg SP, Linde MH, Xu P, Rota C, et al. CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res. 2019;25(8):2560–74. doi:10.1158/1078-0432.Ccr-18-0432. Epub 2019/01/19. PubMed PMID: 30655315; PubMed Central PMCID: PMCPMC8456711.
   PubMed Web of Science ®Google Scholar
• Beatty GL, O’Hara MH, Lacey SF, Torigian DA, Nazimuddin F, Chen F, Kulikovskaya IM, Soulen MC, McGarvey M, Nelson AM, et al. Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial. Gastroenterology. 2018;155(1):29–32. doi:10.1053/j.gastro.2018.03.029. Epub 2018/03/24. PubMed PMID: 29567081; PubMed Central PMCID: PMCPMC6035088.
   PubMed Web of Science ®Google Scholar
• Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, Schmierer M, Gabrusiewicz K, Anderson NR, Petty NE, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38(8):947–53. doi:10.1038/s41587-020-0462-y. Epub 2020/05/04. PubMed PMID: 32361713; PubMed Central PMCID: PMCPMC7883632.
   PubMed Web of Science ®Google Scholar
• Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, et al. Use of CAR-Transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382(6):545–53. doi:10.1056/NEJMoa1910607. Epub 2020/02/06. PubMed PMID: 32023374; PubMed Central PMCID: PMCPMC7101242.
   PubMed Web of Science ®Google Scholar
• Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367(6481):eaba7365. doi:10.1126/science.aba7365. Epub 2020/02/08. PubMed PMID: 32029687.
   PubMed Web of Science ®Google Scholar
• Shi D, Shi Y, Kaseb AO, Qi X, Zhang Y, Chi J, Lu Q, Gao H, Jiang H, Wang H, et al. Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials. Clin Cancer Res. 2020;26(15):3979–89. doi:10.1158/1078-0432.Ccr-19-3259. Epub 2020/05/07. PubMed PMID: 32371538.
   PubMed Web of Science ®Google Scholar
• Tang N, Cheng C, Zhang X, Qiao M, Li N, Mu W, Wei X-F, Han W, Wang H. TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight. 2020;5(4):e133977. doi:10.1172/jci.insight.133977. Epub 2020/01/31. PubMed PMID: 31999649; PubMed Central PMCID: PMCPMC7101140.
   PubMed Web of Science ®Google Scholar
• Reinhard K, Rengstl B, Oehm P, Michel K, Billmeier A, Hayduk N, Klein O, Kuna K, Ouchan Y, Wöll S, et al. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science. 2020;367(6476):446–53. doi:10.1126/science.aay5967. Epub 2020/01/04. PubMed PMID: 31896660.
   PubMed Web of Science ®Google Scholar
• Wang D, Starr R, Chang WC, Aguilar B, Alizadeh D, Wright SL, Yang X, Brito A, Sarkissian A, Ostberg JR, et al. Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma. Sci Transl Med. 2020;12(533):eaaw2672. doi:10.1126/scitranslmed.aaw2672. Epub 2020/03/07. PubMed PMID: 32132216; PubMed Central PMCID: PMCPMC7500824.
   PubMed Web of Science ®Google Scholar
• Brudno JN, Lam N, Vanasse D, Shen YW, Rose JJ, Rossi J, Xue A, Bot A, Scholler N, Mikkilineni L, et al. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nat Med. 2020;26(2):270–80. doi:10.1038/s41591-019-0737-3. Epub 2020/01/22. PubMed PMID: 31959992; PubMed Central PMCID: PMCPMC7781235.
   PubMed Web of Science ®Google Scholar
• Liu G, Rui W, Zheng H, Huang D, Yu F, Zhang Y, Dong J, Zhao X, Lin X. CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma. Eur J Immunol. 2020;50(5):712–24. doi:10.1002/eji.201948457. Epub 2020/01/26. PubMed PMID: 31981231.
   PubMed Web of Science ®Google Scholar
• Singh N, Lee YG, Shestova O, Ravikumar P, Hayer KE, Hong SJ, Lu XM, Pajarillo R, Agarwal S, Kuramitsu S, et al. Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction. Cancer Discov. 2020;10(4):552–67. doi:10.1158/2159-8290.Cd-19-0813. Epub 2020/02/01. PubMed PMID: 32001516; PubMed Central PMCID: PMCPMC7416790.
   PubMed Web of Science ®Google Scholar
• Gudipati V, Rydzek J, Doel-Perez I, Gonçalves VDR, Scharf L, Königsberger S, Lobner E, Kunert R, Einsele H, Stockinger H, et al. Inefficient CAR-proximal signaling blunts antigen sensitivity. Nat Immunol. 2020;21(8):848–56. doi:10.1038/s41590-020-0719-0. Epub 2020/07/08. PubMed PMID: 32632291.
   PubMed Web of Science ®Google Scholar
• Sahoo P, Yang X, Abler D, Maestrini D, Adhikarla V, Frankhouser D, Cho H, Machuca V, Wang D, Barish M, et al. Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data. Interface Focus. 2020;17(162):20190734. doi:10.1098/rsif.2019.0734. Epub 2020/01/16. PubMed PMID: 31937234; PubMed Central PMCID: PMCPMC7014796.
   Google Scholar
• Roth TL, Li PJ, Blaeschke F, Nies JF, Apathy R, Mowery C, Yu R, Nguyen MLT, Lee Y, Truong A, et al. Pooled knockin targeting for genome engineering of cellular immunotherapies. Cell. 2020;181(3):728–44.e21. doi:10.1016/j.cell.2020.03.039. Epub 2020/04/18. PubMed PMID: 32302591; PubMed Central PMCID: PMCPMC7219528.
   PubMed Web of Science ®Google Scholar
• Liu Y, Fang Y, Chen X, Wang Z, Liang X, Zhang T, Liu M, Zhou N, Lv J, Tang K, et al. Gasdermin E–mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Sci Immunol. 2020;5(43):eaax7969. Epub 2020/01/19. doi:10.1126/sciimmunol.aax7969. PubMed PMID: 31953257.
   PubMed Web of Science ®Google Scholar
• Qin L, Zhao R, Chen D, Wei X, Wu Q, Long Y, Jiang Z, Li Y, Wu H, Zhang X, et al. Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth. Biomarker Res. 2020;8:19. doi:10.1186/s40364-020-00198-0. Epub 2020/06/10. PubMed PMID: 32514352; PubMed Central PMCID: PMCPMC7268496.
   PubMed Web of Science ®Google Scholar
• Evgin L, Huff AL, Wongthida P, Thompson J, Kottke T, Tonne J, Schuelke M, Ayasoufi K, Driscoll CB, Shim KG, et al. Oncolytic virus-derived type I interferon restricts CAR T cell therapy. Nat Commun. 2020;11(1):3187. doi:10.1038/s41467-020-17011-z. Epub 2020/06/26. PubMed PMID: 32581235; PubMed Central PMCID: PMCPMC7314766.
   PubMed Web of Science ®Google Scholar
• Yang M, Tang X, Zhang Z, Gu L, Wei H, Zhao S, Zhong K, Mu M, Huang C, Jiang C, et al. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors. Theranostics. 2020;10(17):7622–34. doi:10.7150/thno.43991. Epub 2020/07/21. PubMed PMID: 32685008; PubMed Central PMCID: PMCPMC7359081.
   PubMed Web of Science ®Google Scholar
• Miao L, Zhang J, Zhang Z, Wang S, Tang F, Teng M, Li Y. A bibliometric and knowledge-map analysis of CAR-T cells from 2009 to 2021. Front Immunol. 2022;13:840956. doi:10.3389/fimmu.2022.840956. Epub 2022/04/05. PubMed PMID: 35371087; PubMed Central PMCID: PMCPMC8971369.
   PubMedGoogle Scholar
• Aparicio C, Acebal C, González-Vallinas M. Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review. Exp Hematol Oncol. 2023;12(1):73. doi:10.1186/s40164-023-00435-w. Epub 2023/08/22. PubMed PMID: 37605218; PubMed Central PMCID: PMCPMC10440917.
   PubMed Web of Science ®Google Scholar
• Zhang D, Huang G, Liu J, Wei W. Claudin18.2-targeted cancer theranostics. Am J Nucl Med Mol Imaging. 2023;13(2):64–9. Epub 2023/05/22.PubMed PMID: 37214268; PubMed Central PMCID: PMCPMC10193197.
   PubMed Web of Science ®Google Scholar
• Cao W, Xing H, Li Y, Tian W, Song Y, Jiang Z, Yu J. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy. Biomarker Res. 2022;10(1):38. doi:10.1186/s40364-022-00385-1. Epub 2022/06/02. P ubMed PMID: 35642043; PubMed Central PMCID: PMCPMC9153115.
   PubMed Web of Science ®Google Scholar
• Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, Zhang M, Peng Z, Zhou J, Cao Y, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022;28(6):1189–98. doi:10.1038/s41591-022-01800-8. Epub 2022/05/10. PubMed PMID: 35534566; PubMed Central PMCID: PMCPMC9205778.
   PubMed Web of Science ®Google Scholar
• Qi C, Xie T, Zhou J, Wang X, Gong J, Zhang X, Li J, Yuan J, Liu C, Shen L, et al. CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer. J Hematol Oncol. 2023;16(1):102. doi:10.1186/s13045-023-01491-9. Epub 2023/09/10. PubMed PMID: 37689733; PubMed Central PMCID: PMCPMC10492318.
   PubMed Web of Science ®Google Scholar
• Ma D, Yang B, Guan B, Song L, Liu Q, Fan Y, Zhao L, Wang T, Zhang Z, Gao Z, et al. A bibliometric analysis of pyroptosis from 2001 to 2021. Front Immunol. 2021;12:731933. doi:10.3389/fimmu.2021.731933. Epub 2021/09/07. PubMed PMID: 34484243; PubMed Central PMCID: PMCPMC8416445.
   PubMed Web of Science ®Google Scholar
• Zhang K, Chen H, Li F, Huang S, Chen F, Li Y. Bright future or blind alley? CAR-T cell therapy for solid tumors. Front Immunol. 2023;14:1045024. doi:10.3389/fimmu.2023.1045024. Epub 2023/02/11. PubMed PMID: 36761757; PubMed Central PMCID: PMCPMC9902507.
   PubMed Web of Science ®Google Scholar
• Faulkner C, Palmer A, Williams H, Wragg C, Haynes HR, White P, DeSouza R-M, Williams M, Hopkins K, Kurian KM, et al. EGFR and EGFRvIII analysis in glioblastoma as therapeutic biomarkers. Br J Neurosurg. 2015;29(1):23–9. doi:10.3109/02688697.2014.950631. Epub 2014/08/21. PubMed PMID: 25141189.
   PubMed Web of Science ®Google Scholar
• Abbott RC, Iliopoulos M, Watson KA, Arcucci V, Go M, Hughes-Parry HE, Smith P, Call MJ, Cross RS, Jenkins MR. Human EGFRvIII chimeric antigen receptor T cells demonstrate favorable safety profile and curative responses in orthotopic glioblastoma. Clin Trans Immunol. 2023;12(3):e1440. doi:10.1002/cti2.1440. Epub 2023/03/10. PubMed PMID: 36890859; PubMed Central PMCID: PMCPMC9986233.
   PubMed Web of Science ®Google Scholar
• Yin L, Wan Z, Sun P, Shuai P, Liu Y. Time to abandon CAR-T monotherapy for solid tumors. Biochimica Biophysica Acta Rev Cancer. 2023;1878(4):188930. doi:10.1016/j.bbcan.2023.188930. Epub 2023/06/08. PubMed PMID: 37286147.
   PubMed Web of Science ®Google Scholar
• Alzubi J, Dettmer-Monaco V, Kuehle J, Thorausch N, Seidl M, Taromi S, Schamel W, Zeiser R, Abken H, Cathomen T, et al. PSMA-directed CAR T cells combined with low-dose docetaxel treatment induce tumor regression in a prostate cancer xenograft model. Mol Ther Oncolytics. 2020;18:226–35. doi:10.1016/j.omto.2020.06.014. Epub 2020/07/31. PubMed PMID: 32728611; PubMed Central PMCID: PMCPMC7372156.
   PubMed Web of Science ®Google Scholar
• Qin VM, Haynes NM, D’Souza C, Neeson PJ, Zhu JJ. CAR-T plus radiotherapy: a promising combination for immunosuppressive tumors. Front Immunol. 2021;12:813832. doi:10.3389/fimmu.2021.813832. Epub 2022/02/01. PubMed PMID: 35095911; PubMed Central PMCID: PMCPMC8790144.
   PubMed Web of Science ®Google Scholar
• Lamure S, Herbaux C. Anti-PD-1 therapy can possibly reverse CAR T cells exhaustion in DLBCL. Br J Haematol. 2023;202(2):217–28. doi:10.1111/bjh.18797. Epub 2023/04/05. PubMed PMID: 37013670.
   PubMed Web of Science ®Google Scholar
• Zhang G, Zhao Y, Liu Z, Liu W, Wu H, Wang X, Chen Z. GD2 CAR-T cells in combination with Nivolumab exhibit enhanced antitumor efficacy. Transl Oncol. 2023;32:101663. doi:10.1016/j.tranon.2023.101663. Epub 2023/03/27. PubMed PMID: 36966611; PubMed Central PMCID: PMCPMC10066552.
   PubMed Web of Science ®Google Scholar
• Miao L, Zhang J, Huang B, Zhang Z, Wang S, Tang F, Teng M, Li Y. Special chimeric antigen receptor (CAR) modifications of T cells: a review. Front Oncol. 2022;12:832765. doi:10.3389/fonc.2022.832765. Epub 2022/04/09. PubMed PMID: 35392217; PubMed Central PMCID: PMCPMC8981721.
   PubMed Web of Science ®Google Scholar
• Cox DB, Platt RJ, Zhang F. Therapeutic genome editing: prospects and challenges. Nat Med. 2015;21(2):121–31. doi:10.1038/nm.3793. Epub 2015/02/06. PubMed PMID: 25654603; PubMed Central PMCID: PMCPMC4492683.
   PubMed Web of Science ®Google Scholar
• Wang SW, Gao C, Zheng YM, Yi L, Lu JC, Huang XY, Cai J-B, Zhang P-F, Cui Y-H, Ke A-W. Current applications and future perspective of CRISPR/Cas9 gene editing in cancer. Mol Cancer. 2022;21(1):57. doi:10.1186/s12943-022-01518-8. Epub 2022/02/23. PubMed PMID: 35189910; PubMed Central PMCID: PMCPMC8862238.
   PubMed Web of Science ®Google Scholar
• Dimitri A, Herbst F, Fraietta JA. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Mol Cancer. 2022;21(1):78. doi:10.1186/s12943-022-01559-z. Epub 2022/03/20. PubMed PMID: 35303871; PubMed Central PMCID: PMCPMC8932053.
   PubMed Web of Science ®Google Scholar
• Choi BD, Yu X, Castano AP, Darr H, Henderson DB, Bouffard AA, Larson RC, Scarfò I, Bailey SR, Gerhard GM, et al. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. J Immunother Cancer. 2019;7(1):304. doi:10.1186/s40425-019-0806-7. Epub 2019/11/16. PubMed PMID: 31727131; PubMed Central PMCID: PMCPMC6857271.
   PubMed Web of Science ®Google Scholar
• Liu M, Zhang L, Zhong M, Long Y, Yang W, Liu T, Huang X, Ma X. CRISPR/Cas9-mediated knockout of intracellular molecule SHP-1 enhances tumor-killing ability of CD133-targeted CAR T cells in vitro. Exp Hematol Oncol. 2023;12(1):88. doi: 10.1186/s40164-023-00450-x. Epub 2023/10/07. PubMed PMID: 37803455; PubMed Central PMCID: PMCPMC10559533.
   PubMed Web of Science ®Google Scholar
• Liu Q, Li J, Zheng H, Yang S, Hua Y, Huang N, Kleeff J, Liao Q, Wu W. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T. Mol Cancer. 2023;22(1):28. doi:10.1186/s12943-023-01735-9. Epub 2023/02/09. PubMed PMID: 36750830; PubMed Central PMCID: PMCPMC9903509.
   PubMed Web of Science ®Google Scholar
• Li X, Li W, Xu L, Song Y. Chimeric antigen receptor-immune cells against solid tumors: structures, mechanisms, recent advances, and future developments. Chin Med J. 2023. doi:10.1097/cm9.0000000000002818. Epub 2023/08/29. PubMed PMID: 37640679.
   Google Scholar
• Xiao L, Cen D, Gan H, Sun Y, Huang N, Xiong H, Jin Q, Su L, Liu X, Wang K, et al. Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients. Mol Ther. 2019;27(6):1114–25. doi:10.1016/j.ymthe.2019.03.011. Epub 2019/04/10. PubMed PMID: 30962163; PubMed Central PMCID: PMCPMC6554529.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhu X, Liu H, Wang C, Chen Y, Wang H, Fang Y, Wu X, Xu Y, Li C, et al. The application of HER2 and CD47 CAR-macrophage in ovarian cancer. J Transl Med. 2023;21(1):654. doi:10.1186/s12967-023-04479-8. Epub 2023/09/23. PubMed PMID: 37740183; PubMed Central PMCID: PMCPMC10517545.
   PubMed Web of Science ®Google Scholar
• Fang L, Tian W, Zhang C, Wang X, Li W, Zhang Q, Zhang Y, Zheng J. Oncolytic adenovirus-mediated expression of CCL5 and IL12 facilitates CA9-targeting CAR-T therapy against renal cell carcinoma. Pharmacol Res. 2023;189:106701. doi:10.1016/j.phrs.2023.106701. Epub 2023/02/17. PubMed PMID: 36796464.
   PubMed Web of Science ®Google Scholar
• Wang G, Zhang Z, Zhong K, Wang Z, Yang N, Tang X, Li H, Lu Q, Wu Z, Yuan B, et al. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma. Mol Ther. 2023;31(1):134–53. doi:10.1016/j.ymthe.2022.08.021. Epub 2022/09/04. PubMed PMID: 36056553; PubMed Central PMCID: PMCPMC9840126.
   PubMed Web of Science ®Google Scholar
• Yamamoto TN, Lee PH, Vodnala SK, Gurusamy D, Kishton RJ, Yu Z, Eidizadeh A, Eil R, Fioravanti J, Gattinoni L, et al. T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy. J Clin Invest. 2019;129(4):1551–65. doi:10.1172/jci121491. Epub 2019/01/30. PubMed PMID: 30694219; PubMed Central PMCID: PMCPMC6436880.
   PubMed Web of Science ®Google Scholar